These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E mBio; 2017 Sep; 8(5):. PubMed ID: 28928210 [TBL] [Abstract][Full Text] [Related]
9. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307 [TBL] [Abstract][Full Text] [Related]
10. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Andrade DV; Warnes C; Young E; Katzelnick LC; Balmaseda A; de Silva AM; Baric RS; Harris E Sci Rep; 2019 Nov; 9(1):16258. PubMed ID: 31700029 [TBL] [Abstract][Full Text] [Related]
11. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes. Uno N; Ross TM J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445 [TBL] [Abstract][Full Text] [Related]
12. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922 [TBL] [Abstract][Full Text] [Related]
13. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440 [TBL] [Abstract][Full Text] [Related]
14. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles. Lingemann M; Amaro-Carambot E; Lamirande EW; Pierson TC; Whitehead SS J Virol; 2024 Jul; 98(7):e0068124. PubMed ID: 38953379 [TBL] [Abstract][Full Text] [Related]
19. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787 [TBL] [Abstract][Full Text] [Related]
20. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]